JASPER Early Intervention for Tuberous Sclerosis

Description

The investigators are running an intervention study for young children with Tuberous Sclerosis Complex (TSC). The study will include free play-based behavioral intervention that may improve social and communication skills in children with TSC. Eligible families will have a child in the age range of 12-36 months, with a diagnosis of TSC. A parent must also be available to attend intervention and assessment sessions at the research site (UCLA or BCH). The intervention will focus on teaching caregivers skills to improve the social and communication outcomes of their children. The content of the intervention will be individually tailored to the child's developmental level. The intervention involves 4 on-site assessment visits, and 12 weekly intervention sessions. The intervention focuses on improving social-communication and play skills.

Study Start Date

October, 24 2017

Estimated Completion Date

June 2022

Interventions

  • Behavioral: JASPER

Study ID

University of California, Los Angeles -- IRB #17-000262

Status

Recruiting

Trial ID

NCT03422367

Study Type

Interventional

Trial Phase

N/A

Enrollment Quota

64

Sponsor

University of California, Los Angeles

Inclusion Criteria

  • A confirmed diagnosis of Tuberous Sclerosis Complex

Exclusion Criteria

  • A mental age less than 6 months. A plan for epilepsy surgery during the study participation period.

Gender

All

Ages

6 Months to 40 Months

Accepts Healthy Volunteers

No

Study Locations and Contact Information (2)

Study Location Distance Name Phone Email
Boston Childrens Hospital - Boston, Massachusetts 2.4 miles Jack Keller 857-218-3010 Jack.Keller@childrens.harvard.edu
University of California Los Angeles - Los Angeles, California 2,592.9 miles Carly Hyde BS 310-825-8738 chyde@mednet.ucla.edu

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.